Westpac Banking Corp boosted its position in Incyte Corporation (NASDAQ:INCY) by 11.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,798 shares of the biopharmaceutical company’s stock after buying an additional 1,117 shares during the period. Westpac Banking Corp’s holdings in Incyte Corporation were worth $1,018,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of INCY. Mitsubishi UFJ Trust & Banking Corp increased its position in Incyte Corporation by 2.9% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 344,410 shares of the biopharmaceutical company’s stock worth $32,474,000 after buying an additional 9,635 shares during the period. Asymmetry Capital Management L.P. increased its position in Incyte Corporation by 46.6% in the third quarter. Asymmetry Capital Management L.P. now owns 37,407 shares of the biopharmaceutical company’s stock worth $3,527,000 after buying an additional 11,897 shares during the period. Princeton Alpha Management LP purchased a new position in Incyte Corporation during the third quarter worth approximately $1,345,000. American International Group Inc. increased its position in Incyte Corporation by 4.1% in the third quarter. American International Group Inc. now owns 17,183 shares of the biopharmaceutical company’s stock worth $1,620,000 after buying an additional 674 shares during the period. Finally, JGP Global Gestao de Recursos Ltda. purchased a new position in Incyte Corporation during the third quarter worth approximately $427,000. Institutional investors and hedge funds own 91.91% of the company’s stock.

Institutional Ownership by Quarter for Incyte Corporation (NASDAQ:INCY)

Shares of Incyte Corporation (NASDAQ:INCY) traded up 0.17% during midday trading on Friday, reaching $117.75. The company had a trading volume of 1,102,974 shares. The company has a market capitalization of $22.18 billion, a P/E ratio of 158.27 and a beta of 0.83. Incyte Corporation has a 12 month low of $55.00 and a 12 month high of $121.18. The firm’s 50 day moving average price is $103.29 and its 200-day moving average price is $90.50.

COPYRIGHT VIOLATION WARNING: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was illegally copied and republished in violation of US & international copyright and trademark law. The legal version of this piece can be viewed at http://www.watchlistnews.com/westpac-banking-corp-increases-stake-in-incyte-corporation-incy/1060742.html.

A number of equities analysts recently commented on the company. Cowen and Company reiterated an “outperform” rating on shares of Incyte Corporation in a research note on Thursday. BMO Capital Markets reiterated a “buy” rating and issued a $135.00 price target (up from $122.00) on shares of Incyte Corporation in a research note on Tuesday. RBC Capital Markets reiterated a “buy” rating on shares of Incyte Corporation in a research note on Monday, December 5th. Zacks Investment Research downgraded Incyte Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, November 29th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $115.00 price target (up from $101.00) on shares of Incyte Corporation in a research note on Sunday, November 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $103.55.

In related news, EVP Reid M. Huber sold 11,739 shares of the company’s stock in a transaction dated Monday, January 9th. The shares were sold at an average price of $113.55, for a total value of $1,332,963.45. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Paula J. Swain sold 10,000 shares of the company’s stock in a transaction dated Thursday, October 20th. The shares were sold at an average price of $90.00, for a total transaction of $900,000.00. Following the completion of the sale, the executive vice president now directly owns 39,248 shares in the company, valued at approximately $3,532,320. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by corporate insiders.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK).

5 Day Chart for NASDAQ:INCY

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY).

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.